Mazdutide vs Tirzepatide

Overview

Mazdutide (IBI362/LY3305677) is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics in partnership with Eli Lilly, primarily studied in Chinese populations. Tirzepatide is Lilly’s globally approved GLP-1/GIP dual agonist.

Key distinction: Mazdutide uses glucagon co-agonism (like pemvidutide), while tirzepatide uses GIP co-agonism. Mazdutide’s development has focused on China with limited Western data.

Key Facts

Aspect	Mazdutide	Tirzepatide
Developer	Innovent / Eli Lilly	Eli Lilly
Class	GLP-1/Glucagon dual agonist	GLP-1/GIP dual agonist
FDA Status	Not approved	Approved
China Status	Phase 3 / Approved for obesity (2024)	Approved

Mechanism Comparison

Aspect	Mazdutide	Tirzepatide
GLP-1 Receptor	Agonist	Agonist
Second Target	Glucagon receptor	GIP receptor
Approach	Energy expenditure focus	Metabolic/insulin focus
Ratio	Balanced GLP-1/glucagon	Weighted toward GIP

How They Work

Mazdutide:

• Balanced dual agonist at GLP-1 and glucagon receptors
• GLP-1 reduces appetite and improves glycemic control
• Glucagon increases energy expenditure and hepatic lipid oxidation
• May have distinct metabolic profile from GIP-based approaches

Tirzepatide:

• Dual agonist at GLP-1 and GIP receptors
• Strong GLP-1 effects for appetite and glucose
• GIP enhances overall metabolic effects
• Well-established mechanism and efficacy

Evidence Quality

Mazdutide Research

Trial Phase	Status	Key Findings
Phase 2 (China)	Completed	Weight loss ~11-12% at 24 weeks
Phase 3 GLORY (Obesity)	Completed	~16-18% weight loss
Phase 3 (T2D, China)	Completed	A1c reductions demonstrated
Western trials	Limited	Primarily Chinese data

Current evidence:

• Approved in China for obesity (2024)
• Most data from Chinese populations
• Limited Western/global clinical data
• Efficacy appears similar to class

Tirzepatide Research

Trial Phase	Status	Key Findings
SURPASS (Global)	Completed	Robust T2D efficacy
SURMOUNT (Global)	Completed	20-22% weight loss
Post-marketing	Extensive	Real-world data available
Diverse populations	Yes	Broad demographic data

Established evidence:

• Global Phase 3 programs completed
• Diverse patient populations studied
• Approved in US, EU, Japan, China, and many other markets
• Extensive post-marketing experience

Efficacy Comparison

Weight Loss

Metric	Mazdutide	Tirzepatide
Phase 3 weight loss	~16-18%	~20-22%
Trial populations	Primarily Chinese	Global
Duration	48 weeks	72 weeks
Comparability	Limited	Gold standard

Population considerations: BMI and metabolic characteristics differ between Asian and Western populations, making direct efficacy comparisons challenging.

Glycemic Control

Metric	Mazdutide	Tirzepatide
A1c reduction	~1.5-2.0%	~1.5-2.4%
Trial population	Chinese T2D	Global T2D
Evidence quality	Moderate	High

Evidence Strength Comparison

Factor	Mazdutide	Tirzepatide
Global peer-reviewed studies	Limited	Extensive
Western Phase 3 trials	None	Multiple
Chinese Phase 3 trials	Multiple	Yes
Regulatory approval (US)	No	Yes
Overall global evidence	Moderate (regional)	High

Side Effects

Mazdutide (Chinese Trial Data)

Side Effect	Incidence	Notes
Nausea	~20-30%	GLP-1 class effect
Vomiting	~10-15%	Common
Diarrhea	~10-15%	GI effects expected
Decreased appetite	Common	Expected mechanism
Hypoglycemia	Low	With concomitant therapy

Tirzepatide (Established Profile)

Side Effect	Incidence	Notes
Nausea	12-33%	Dose-dependent
Diarrhea	12-21%	Usually transient
Vomiting	5-12%	Improves with titration
Constipation	6-12%	Common

Safety Considerations

Mazdutide:

• Glucagon component theoretical concerns (hyperglycemia)
• Clinical data suggests adequate glucose control maintained
• Limited long-term global safety data
• Post-marketing surveillance in China ongoing

Tirzepatide:

• Well-characterized global safety profile
• GI side effects most common
• Rare pancreatitis risk
• Extensive pharmacovigilance data

Regulatory Status

Region	Mazdutide	Tirzepatide
United States	Not approved	Approved (Mounjaro, Zepbound)
European Union	Not approved	Approved
China	Approved (obesity, 2024)	Approved
Japan	Not approved	Approved
Global availability	Limited to China	Broadly available

Development Strategy Comparison

Mazdutide Path

Aspect	Status
Primary market	China
Development partner	Eli Lilly (licensed from Lilly)
Global expansion	Uncertain
NASH development	Potential

Tirzepatide Path

Aspect	Status
Primary market	Global
Expansion	Ongoing in multiple indications
NASH development	Phase 3 ongoing
Heart failure	SUMMIT trial completed

Practical Comparison

Factor	Mazdutide	Tirzepatide
Availability (US)	Not available	Prescription
Availability (China)	Available	Available
Route	Subcutaneous	Subcutaneous

Who Might Consider Each

Tirzepatide (Available Globally):

• Patients in US, EU, and most markets
• Type 2 diabetes or obesity indications
• Those wanting globally approved therapy
• Standard of care in many regions

Mazdutide:

• Primarily available in China
• Alternative option in Chinese market
• Those interested in glucagon-based approach
• Not currently an option outside China

Summary

Factor	Mazdutide	Tirzepatide
Evidence quality (Global)	Low-Moderate	High
Evidence quality (China)	Moderate-High	High
Weight loss	~16-18%	~20-22%
Mechanism	GLP-1/Glucagon	GLP-1/GIP
US Availability	No	Yes
China Availability	Yes	Yes

Key takeaway: Tirzepatide is the globally available standard with extensive data. Mazdutide represents an alternative dual agonist approach primarily available in China. For patients outside China, tirzepatide is the accessible option; mazdutide’s global expansion remains uncertain.

---

This comparison is for educational purposes only. Mazdutide is approved only in China; tirzepatide requires a prescription. Consult a healthcare provider for treatment decisions.